Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | NPY1R | P25929 | 1/20 | 0.58 |
| ▸ | NPY2R | P49146 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11667316 | 0.84 | NPC1 (0.59) | CYP3A4MAPTALDH1A1ALOX15MEN1 | |
| SCHEMBL11640106 | 0.84 | CYP3A4 (0.50) | CYP3A4EPHX1EPHX2MAPTNPSR1 | |
| SCHEMBL27833985 | 0.84 | TSHR (0.71) | MAPTNPSR1ALDH1A1MEN1NPC1 | |
| SCHEMBL4003878 | 0.83 | CYP3A4 (0.71) | CYP3A4EPHX1EPHX2MAPTNPSR1 | |
| SCHEMBL30833308 | 0.83 | CYP3A4 (0.71) | CYP3A4EPHX1EPHX2MAPTNPSR1 | |
| SCHEMBL15107476 | 0.81 | L3MBTL1 (0.74) | CYP3A4EPHX1EPHX2MAPTNPSR1 | |
| SCHEMBL7932797 | 0.81 | CYP3A4 (0.69) | CYP3A4EPHX1EPHX2MAPTNPSR1 | |
| Propanil SCHEMBL21900164 | 0.81 | CYP3A4 (1.00) | CYP3A4EPHX1EPHX2MAPTNPSR1 | |
| Propanil SCHEMBL26871 | 0.81 | CYP3A4 (1.00) | CYP3A4EPHX1EPHX2MAPTNPSR1 | |
| Propanil SCHEMBL1702271 | 0.81 | CYP3A4 (1.00) | CYP3A4EPHX1EPHX2MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108276323-B | 3-functionalized N (O, S) -heteroandene derivatives and application thereof in respiratory syncytial virus resistance | 北京交通大学 | 2020-12-29 | — | — | CN | disclosed |
| CN-108276323-A | N (O, S)-miscellaneous indene derivative of a kind of 3- function dough and its application in anti respiratory syncytial virus | 北京交通大学 | 2018-07-13 | — | — | CN | disclosed |
| EP-2069286-B1 | INHIBITORS FOR GLYT-1 | HOFFMANN LA ROCHE (CH) | 2012-09-19 | — | — | EP | disclosed |
| US-7589089-B2 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-2069286-A1 | INHIBITORS FOR GLYT-1 | F. Hoffmann-Roche AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| US-20080058331-A1 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2008025694-A1 | INHIBITORS FOR GLYT-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-06 | — | — | WO | disclosed |
| EP-1077701-A4 | ANTI-VIRAL COMPOUNDS | LILLY CO ELI (US) | 2002-03-20 | — | — | EP | disclosed |
| EP-1077701-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
| US-4160017-A | EMETIC AGENTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1979-07-03 | — | — | US | disclosed |
| US-4102924-A | REACTING ACYLAMINO-ARYLS WITH HALO-ARYLS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058331-A1 | Inhibitors for GlyT-1 | GLRA1, SLC1A2, AGXT | CYP3A4 915/4885EPHX1 1365/4885EPHX2 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.